The omens look good for the upcoming Pulsar readout, but can Eylea keep its wet AMD stranglehold?
The group will need longer-term data to justify its huge valuation.
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
But data are early, and other groups are also developing less frequent injections for wet AMD.